Another study tested the use of colchicine in higher doses (1.2 mg followed by 0.6 mg after 1 h) in patients with CAD who underwent elective coronary angioplasty, without finding a reduction in the incidence of myocardial injury or MACE outcomes (any death, non-fatal AMI, or target vessel revascularization) within 30 days of its use, but the medication was associated with an attenuation in CRP and IL-6 values within up to 24 h [26]. The gene discussed is CRP; the disease is coronary artery disorder.